Table 5

Measures of aggressiveness of end-of-life care in patients with acute myeloid leukaemia receiving ePSC or late referral PC

ePSCLate PCRD, % (95% CI)P value
n/n%n/n%
Chemotherapy
Within 90 days of death19/7525.317/3647.2−21.9 (−40.9 to −2.8)0.0211
Within 30 days of death7/759.310/3627.8−18.4 (−34.5 to −2.4)0.0115
Within 14 days of death*2/752.75/3613.9−11.2 (−23.1 to 0.65)0.0228
ICU admission
 Within 30 days of death*0/7505/3414.7−14.7 (−26.6 to −2.8)0.0007
Intubation
 Within 30 days of death*0/7502/336.1−6.1 (−14.2 to 2.1)0.0314
CPR
 Within 30 days of death*0/7500/40NENEN.E.
Access to ED
≥2 within 30 days of death*3/7548/3423.5−19.5 (−34.5 to −4.6)0.001
Within 30 days of death29/7538.718/3452.9−14.3 (−34.3 to 5.8)0.1633
Within 14 days of death20/7526.715/3444.1−17.5 (−36.9 to 2.0)0.0706
Hospitalisation
 ≥2 within 30 days of death*3/7544/3411.8−7.8 (−19.5 to 3.9)0.1255
Home/hospice care service
Inpatient hospice service11/7514.73/378.116.6 (−5.3 to 18.5)0.3236
Hospice length of stay >7 days*8/7510.72/4055.7 (−4.1 to 15.4)0.3043
Home-care service48/756412/403034 (16.1 to 51.9)0.0005
Opiate use
 Within 30 days of death44/7558.715/3740.518.1 (−1.2 to 37.5)0.0707
Place of death
Hospice or home38/7550.711/3630.620.1 (1.3 to 38.9)0.0458
Hospital33/754425/3669.4−25.4 (−44.2 to −6.7)0.012
Acute facility*4/755.311/3531.4−26.1 (−42.3 to −9.9)0.002
No red cell transfusion
 Within 7 days of death*37/7549.39/3228.1222.5 (3.3 to 41.8)0.0315
No platelet transfusion
 Within 7 days of death*31/7541.39/3228.1613.2 (−5.9 to 32.4)0.1960
  • *Indicators of aggressiveness of care at the end of life.16 32

  • CPR, cardiopulmonary resuscitation; ED, emergency department; ePSC, early palliative supportive care; ICU, intensive care unit; NE, not evaluable; late PC, late referral to palliative care; RD, risk difference.